Prospective Open-Label Phase II Trial of Individualized Anti-Thymocyte Globulin for Improved T-Cell Reconstitution after Pediatric Allogeneic Hematopoietic Cell Transplantation: The Parachute-Study
Rick Admiraal(NHS Blood and Transplant), Jaap Jan Boelens(Wilhelmina Children's Hospital), C. Michel Zwaan(Hôpital Saint-Michel), Robbert G. M. Bredius(Leiden University Medical Center), Ineke van Vliet, Caroline A. Lindemans(University Medical Center Utrecht), Marc Bierings(University Medical Center Utrecht), A. Birgitta Versluijs(NHS Blood and Transplant), Stefan Nierkens(Utrecht University), Marta Lopez Yurda(Princess Máxima Center)
Cited by 10
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
|Nature Genetics|2007|387